Stifel Financial
CLDX icon

Stifel Financial’s Celldex Therapeutics CLDX Stock Holding History

Stifel Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,353
Closed -$90K – 2401
2016
Q2 		$90K Buy
1,353
+26
+2% +$1.65K ﹤0.01% 2393
2016
Q1 		$75K Sell
1,327
-267
-17% -$30K ﹤0.01% 2137
2015
Q4 		$375K Buy
1,594
+600
+60% +$131K ﹤0.01% 1808
2015
Q3 		$159K Buy
994
+27
+3% +$7.64K ﹤0.01% 2078
2015
Q2 		$366K Sell
967
-330
-25% -$131K ﹤0.01% 1853
2015
Q1 		$543K Buy
1,297
+73
+6% +$26.1K ﹤0.01% 1580
2014
Q4 		$335K Buy
+1,224
New +$304K ﹤0.01% 1815
2014
Q2 		– Sell
-15,595
Closed -$4.13M – 2207
2014
Q1 		$4.13M Buy
+15,595
New +$5.97M 0.04% 499

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Stifel Financial's CLDX Position: Q3 2016 in Review

Stifel Financial sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 1,353 shares — an estimated $90K sold.

Stifel Financial first reported a position in CLDX in Q1 2014 and held it in 8 quarters. The position peaked at $4.13M in Q1 2014. 139 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

  • Stifel Financial reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Stifel Financial sold 1,353 Celldex Therapeutics shares in Q3 2016, an estimated $90K.
  • Stifel Financial first reported a position in Celldex Therapeutics in Q1 2014 and held it in 8 quarters.
  • Stifel Financial's Celldex Therapeutics position peaked at $4.13M in Q1 2014.
  • 139 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on Stifel Financial's 13F filing for Q3 2016, filed 15 Nov 2016.